Eledon Pharmaceuticals Inc (ELDN) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Eledon Pharmaceuticals Inc (ELDN) has a cash flow conversion efficiency ratio of -0.103x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-14.09 Million) by net assets ($136.78 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see ELDN stock market capitalisation for the company's overall valuation and market capitalisation.
Eledon Pharmaceuticals Inc - Cash Flow Conversion Efficiency Trend (2012–2025)
This chart illustrates how Eledon Pharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Eledon Pharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Eledon Pharmaceuticals Inc ranked by their cash flow conversion efficiency. Explore cash flow quality index of Eledon Pharmaceuticals Inc to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Dynamix Corporation III Class A Ordinary Shares
NASDAQ:DNMX
|
-0.002x |
|
Appen Ltd
AU:APX
|
-0.044x |
|
Stack Capital Group Inc
TO:STCK
|
-0.009x |
|
EASY HOLDINGS Co. Ltd
KQ:035810
|
0.037x |
|
Adgar Investments and Development Ltd
TA:ADGR
|
0.019x |
|
Nova Lifestyle I
NASDAQ:NVFY
|
-0.140x |
|
Camlin Fine Sciences Limited
NSE:CAMLINFINE
|
0.078x |
|
Hester Biosciences Limited
NSE:HESTERBIO
|
0.050x |
Annual Cash Flow Conversion Efficiency for Eledon Pharmaceuticals Inc (2012–2025)
The table below shows the annual cash flow conversion efficiency of Eledon Pharmaceuticals Inc from 2012 to 2025. View Eledon Pharmaceuticals Inc stock quote for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $136.78 Million | $-62.34 Million | -0.456x | -13.91% |
| 2024-12-31 | $118.14 Million | $-47.27 Million | -0.400x | +15.56% |
| 2023-12-31 | $83.42 Million | $-39.53 Million | -0.474x | -40.34% |
| 2022-12-31 | $84.18 Million | $-28.42 Million | -0.338x | -91.51% |
| 2021-12-31 | $164.00 Million | $-28.91 Million | -0.176x | -120.90% |
| 2020-12-31 | $190.60 Million | $-15.21 Million | -0.080x | +94.55% |
| 2019-12-31 | $9.46 Million | $-13.86 Million | -1.464x | -78.40% |
| 2018-12-31 | $14.49 Million | $-11.89 Million | -0.821x | -6.84% |
| 2017-12-31 | $19.45 Million | $-14.94 Million | -0.768x | +43.51% |
| 2016-12-31 | $26.86 Million | $-36.52 Million | -1.360x | -103.53% |
| 2015-12-31 | $61.72 Million | $-41.24 Million | -0.668x | -227.38% |
| 2014-12-31 | $103.50 Million | $-21.12 Million | -0.204x | -172.87% |
| 2013-12-31 | $-55.27 Million | $-15.48 Million | 0.280x | +19.72% |
| 2012-12-31 | $-39.90 Million | $-9.33 Million | 0.234x | -- |
About Eledon Pharmaceuticals Inc
Eledon Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. It uses its immunology expertise in targeting the CD40 Ligand (CD40L) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS). The company's lead compound in development is tegoprubart, an IgG1 and anti-CD40L antibody with high affinity for C… Read more